Browsing by Author

Jump to a point in the index:
Showing results 21 to 40 of 156 < previous   next >
Issue DateTitleAuthor(s)TypePreview
2002Apolipoproteins and prediction of fatal myocardial infarction [5] (multiple letters)Wägner, Ana María ; Ordóñez-Llanos, Jordi; Walldius, Göran; Jungner, Ingmar; Aastveit, Are, et alComentario
2002Diabetes mellitus and cardiovascular diseaseWägner, A. M. ; Martínez-Rubio, A.; Ordóez-Llanos, J.; Pérez-Pérez, A.Reseña
2002LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetesWägner, A. M. ; Jorba, O.; Rigla, M.; Alonso, E.; Ordóñez-Llanos, J., et alArtículo
2002Hypothyroidism as a cause of rhabdomyolysisBarahona, Maria José; Mauri, Albert; Sucunza, Nuria; Paredes, Roger; Wägner, Ana María Artículo
2002Diabetic dyslipidemia: Assessment and treatmentWägner, Ana M. ; Pérez, AntonioArtículo
2003Is necessary to reduce the LDL cholesterol level below 100 mg/dl in all diabetic patients? (multiple letters) [1]Wägner, Ana M. ; Pérez, AntonioComentario
2003Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patientsWagner, Ana Maria ; Perez, Antonio; Zapico, Edgar; Ordóñez-Llanos, JordiArtículo
2003The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patientsWägner, Ana María ; Zapico, Edgar; Bonet, Rosa; Pérez, Antonio; Ordóñez-Llanos, JordiArtículo
2003Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetesWägner, Ana María ; Jorba, Oscar; Rigla, Mercedes; Bonet, Rosa; De Leiva, Alberto, et alArtículo
2003Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudySillesen, Henrik; Albers, Gregory; Altafullah, Irfan; Benavente, Oscar; Book, Diane, et alArtículo
2003Thyroid carcinomas of the follicular epithelium: Tumor markers and oncogenesÁlvarez-Núñez, Francisco; Mora, Josefina; Matías-Guiu, Xavier; Bagué, Silvia; de Leiva Hidalgo, Alberto, et alReseña
2003Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretionWägner, Ana M. ; Ordóñez-Llanos, Jordi; Arcelus, Rosa; Bonet, Rosa; Jorba, Oscar, et alArtículo
2003Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemiaWägner, Ana M. ; Jorba, Oscar; Bonet, Rosa; Ordóñez-Llanos, Jordi; Pérez, AntonioArtículo
2004Pancreatic vasoactive intestinal peptide-producing tumor and hypercalcemia [1]Wägner, Ana M. ; Trías, Manel; Campo, Rafel; López, Josefa; Rodríguez, Manuel, et alComentario
2004Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetesWägner, Ana M. ; Ordóñez-Llanos, Jordi; Jorba, Oscar; Pérez, AntonioComentario
2005Hemolyzed plasma samples in diabetic ketoacidosis (DKA) [2]Sojo, L.; Wägner, A. M. ; Ordóñez, J.; Corcoy, R.Comentario
2005Triglyceride-to-HDL cholesterol ratio in the dyslipidemic classification of type 2 diabetesWägner, Ana María ; Pérez, Antonio; Sánchez-Quesada, Jose Luis; Ordóñez-Llanos, JordiArtículo
2005European type 1 diabetes genetics networkWägner, A. M. ; Mauricio, D.; Argente, J.; Ampudia, F. J.; Castaño, L., et alArtículo
2005Patients with MEN-1 are more insulin-resistant than their non-affected relativesWägner, Ana M. ; Martín-Campos, Jesus M.; Mayoral, Carmen; De Leiva, Alberto; Blanco-Vaca, FranciscoArtículo
2005Determinants of neurosurgical outcome in pituitary tumorsBarahona, M. J.; Sojo, L.; Wägner, A. M. ; Bartumeus, F.; Oliver, B., et alArtículo